Loading company
CG Oncology, Inc.
CGON · Nasdaq · ·
$70.56+1.2%Sep 29 close
- 1M
- -5.1%
- 6M
- +10.3%
- 1Y
- +75.2%
CGON · Nasdaq · ·
$70.56+1.2%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.2M | $0.00 | — |
| Profit | -$79.1M | -$41.4M | -90.84% |
| Profit per share | -$0.90 | -$0.54 | -66.67% |
| Free Cash Flow | -$46.9M | -$28M | -67.60% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
CG Oncology, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 600 patients with Non-Muscle Invasive Bladder Cancer (NMIBC). This program includes two Phase 3 clinical trials: BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC. CG Oncology also has a multi-cohort Phase 2 trial, CORE-008, evaluating the safety and efficacy of cretostimogene in high-risk NMIBC. Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet certain program eligibility requirements. Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from CG Oncology, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.